证券代码：603233 证券简称：大参林 公告编号：2026-001 转债代码：113605 转债简称：大参转债 大参林医药集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 可转债发行上市概况 （一） 可转债发行情况 大参林医药集团股份有限公司（以下简称"公司"）经中国证券监督管理委 员会证监许可[2020]1981号文核准，于2020年10月22日公开发行了14,050,000张 可转换公司债券，每张面值100元，发行总额为人民币140,500.00万元。经上海证 券交易所自律监管决定书【2020】370号文同意，可转换公司债券于2020年11月 13日起在上海证券交易所挂牌交易，债券简称"大参转债"，债券代码"113605"。 2023年5月19日，公司召开2022年年度股东大会并审议通过了《关于2022年 度利润分配及资本公积金转增股本的议案》，同意公司以实施权益分派股权登记 日登记的总股本为基数，每10股派发现金红利6元（含税），以资本公积金向全体 股 ...

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Group 1 - The core viewpoint of the news is that Dazhonglin's stock performance and financial metrics indicate a mixed outlook, with low financing balance and high short-selling volume [1][2] - As of December 26, Dazhonglin's financing balance is 2.11 billion yuan, which is 1.02% of its market capitalization, indicating a low financing level compared to the past year [1] - The company reported a revenue of 20.068 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 1.71%, while net profit attributable to shareholders increased by 25.97% to 1.081 billion yuan [2] Group 2 - Dazhonglin has distributed a total of 3.740 billion yuan in dividends since its A-share listing, with 2.009 billion yuan distributed in the last three years [3] - The number of shareholders decreased by 9.38% to 28,600 as of September 30, while the average number of circulating shares per person increased by 10.35% to 39,833 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 84.9429 million shares, a decrease of 5.505 million shares from the previous period [3]

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Summary of the Conference Call for Dazhonglin Company Overview - Dazhonglin is a leading retail pharmacy company in China, established in 1999 and headquartered in Guangzhou. The company has maintained stable and rapid expansion since its inception, with a total of 17,385 stores across 21 provinces as of Q3 2025, including over 10,000 direct-operated stores and more than 7,000 franchise stores [2][5][12]. Key Points and Arguments Optimistic Performance Outlook - Dazhonglin anticipates optimistic performance in Q4 2025, despite short-term impacts from flu prevalence expected between November 2025 and January 2026. These short-term factors are expected to mitigate the industry's growth slowdown [2][3]. Strategic Transformation - The company has proactively closed over 400 inefficient stores, shifting from scale competition to a quality-first approach. This transformation is supported by supply chain advantages, digital capabilities, and refined operational systems, allowing Dazhonglin to capture market share while stabilizing its base in South China [2][3][7]. Asset-Light Franchise Model - Dazhonglin is transitioning to an asset-light franchise model, with over 7,000 franchise stores contributing to a total of 17,385 stores as of Q3 2025. This model enhances expansion efficiency and single-store profitability [2][3][7]. High Return on Equity (ROE) - The company's ROE is significantly higher than the industry average, indicating superior capital efficiency and profitability. Dazhonglin achieves high-quality growth through direct-operated franchise expansion, efficient operations, and strong cash flow [2][3]. Smart Logistics Center - The launch of the Shunde Smart Logistics Center, a benchmark project in China's pharmacy retail industry, enables 24-hour coverage of the Pearl River Delta and nationwide delivery within 72 hours. This logistics capability aids in cost control and profit enhancement [2][4][7]. Regulatory Changes - The government has lifted restrictions on the sale of non-pharmaceutical products in chain pharmacies, allowing for the sale of all non-drug items. This policy is expected to improve store space utilization and contribute to rapid growth in the overall industry scale [2][11]. Product Strategy and Future Outlook - Dazhonglin has developed over 1,000 proprietary brands, including traditional Chinese medicine and health supplements, to enhance profit margins by reducing reliance on third-party suppliers. The company aims to establish a customer system centered around chronic disease management services [2][13]. Membership System - The company boasts a large and active membership system, with a significant increase in active members contributing to higher average transaction values. Dazhonglin's profit growth is close to 30% year-on-year for the first three quarters, with optimistic projections for double-digit revenue growth in the coming year [2][14]. Additional Important Insights Industry Challenges - The domestic retail pharmacy market is experiencing a slowdown in growth, posing challenges for the industry. However, Dazhonglin's strategic measures, including store closures and a focus on high-margin products, are helping maintain growth and long-term competitiveness [6][10]. Prescription Drug Sales - The retail sector faces challenges in prescription drug sales, with only about 20% of prescriptions being filled at retail outlets, compared to 80% in countries like Japan and the U.S. This presents an opportunity for growth in the retail pharmacy sector as prescription flows are expected to increase [8][9]. Competitive Landscape - The concentration and chain rate in the domestic pharmaceutical industry have significant room for improvement. As the industry slows, smaller players may either join larger chains or close down, leading to an expected increase in chain rates over the next two to three years [10].

Core Viewpoint - The domestic chain pharmacy industry is entering a period of negative growth, with a significant reduction in the number of pharmacies and a shift from rapid expansion to a focus on value enhancement and health services [2][3][11] Industry Overview - By Q1 2025, the total number of pharmacies in China is expected to fall below 700,000, with a net decrease of approximately 3,000 stores in a single quarter, indicating a widespread "store closure wave" [2] - The overall market size for pharmaceuticals is projected to reach 2.03 trillion yuan in 2024, but the growth rate is only 0.9%, with a forecasted decline to 1.97 trillion yuan in 2025 [2] Company Performance - Major chain pharmacies are experiencing divergent performance: Dazhenglin reported a net profit of 1.081 billion yuan in the first three quarters of 2025, up 25.97% year-on-year; Yifeng Pharmacy's net profit reached 1.225 billion yuan, a 10.27% increase; while Yixintang faced a decline with a net profit of 269 million yuan, down 8.17% [2] Store Closure Trends - Predictions indicate that the number of pharmacy closures in 2025 could reach between 50,000 and 100,000, marking a shift from the previous era of aggressive expansion to a focus on operational efficiency [3][4] - The industry is expected to return to a more reasonable scale of around 500,000 pharmacies, similar to levels seen in 2018 [4] Market Dynamics - The closure wave is driven by oversupply and increased regulatory pressures, with a significant rise in the proportion of non-pharmaceutical sales, which reached 34.6% in 2025, up 5.2 percentage points from 2024 [5] - The market share of the top ten pharmacy brands increased to 58% in Q3 2025, reflecting a growing concentration in the industry as smaller players exit [5] Business Model Evolution - The franchise model is becoming a key strategy for leading pharmacy chains to expand market share, with significant increases in franchise store openings reported [6] - The industry is transitioning from a focus on selling drugs to providing health services, with a notable shift towards a "sell health" approach [6][7] Professionalization and Service Enhancement - Professionalization is identified as a core development direction, with leading companies adopting innovative drug and DTP pharmacy models to enhance service delivery [7] - Community pharmacies are increasingly focusing on chronic disease management, with a significant percentage of patients expressing a desire for medication guidance and health management services [8] Diversification and Digital Transformation - Leading pharmacies are diversifying their offerings to include health-related products and services, transforming into comprehensive health experience hubs [9] - The integration of online and offline channels is accelerating, with significant growth in new retail segments and contributions from O2O channels [9] Future Outlook - Despite current challenges, industry experts believe that the long-term trend for the chain pharmacy sector remains positive, driven by supply-side adjustments and demand recovery [10] - The future of pharmacies is expected to focus on building a diversified health service ecosystem, aligning with national health strategies and enhancing both social and economic benefits [10][11]

Group 1 - The pharmacy sector experienced a short-term decline, with stocks such as Shuyupingmin falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, also saw a drop in their stock prices [1]

Group 1 - The pharmacy sector has experienced a short-term decline, with major companies such as Xu Yu Ping Min falling over 6% [1] - Other companies in the sector, including First Pharmaceutical, Dazhenglin, Yixintang, and Jianzhijia, have also seen declines in their stock prices [1]

Core Viewpoint - Dazhonglin has been recognized as a leading company in ESG practices within the pharmaceutical retail industry, marking a significant achievement in its sustainable development strategy [1][2] Group 1: Company Overview - Dazhonglin, one of China's largest chain pharmacies, had 17,385 stores as of the end of Q3 2025, including 7,029 franchise stores, with a total operating area of 887,503 square meters [1] - In the first nine months of 2025, the company added 832 new stores, continuing its strategy of expanding its presence in South China while penetrating weaker regions through self-built, acquisition, and direct franchise models [1] Group 2: ESG Practices - Dazhonglin has achieved quantifiable results in its ESG initiatives, including energy management, the use of new energy delivery vehicles, and the implementation of paperless operations, resulting in approximately 154.33 million kWh of solar power generated in 2024 and saving around 25.24 million cardboard boxes [2] - The company has engaged in community service through public donations and health management services, conducting over 40,000 health education activities and providing health monitoring services to over 1 million residents, positioning itself as a "community health service station" [2] - Dazhonglin emphasizes strong corporate governance as a foundation for sustainable development, maintaining a transparent governance structure and robust risk management, which supports its compliance and ethical business practices [2] Group 3: Future Outlook - The company's ESG practices reflect a shift from compliance management to value-driven operations, enhancing its long-term competitiveness and providing a reference for sustainable development in the industry [2] - With the growing demand for chronic disease management in an aging society, Dazhonglin's integrated approach of "medicine + pharmacy + insurance" is expected to further unlock synergies between ESG and commercial value [2]